Jasper Therapeutics (JSPR)
(Delayed Data from NSDQ)
$2.98 USD
+0.01 (0.34%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $2.98 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
JSPR 2.98 +0.01(0.34%)
Will JSPR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for JSPR based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for JSPR
Jasper Therapeutics (JSPR) Restructures to Focus on Briquilimab Development | JSPR Stock News
Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to ...
Jasper Therapeutics to reduce workforce by 50%, focus on Chronic Urticaria
JSPR: Jasper Therapeutics Faces Major Price Target Adjustment | JSPR Stock News
Evercore ISI Group Lowers Price Target for Jasper Therapeutics (JSPR) | JSPR Stock News